Formulation for immunization of pigs by the oral route
The combination of chimeric proteins like E2CD154 with cdAMP in oral formulations addresses the limitations of existing vaccines by inducing effective immune responses and protecting against CSF and ASF in pigs, offering a safer and more reliable immunization method.
Patent Information
- Application Number
- PCT/CU2024/050003
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-18
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-21
AI Technical Summary
Current oral vaccines for pigs, particularly against Classical Swine Fever (CSF) and African Swine Fever (ASF), face challenges such as instability in the digestive tract, tolerance induction instead of immunity, dependence on a cold chain, and interference from neutralizing antibodies, limiting their effectiveness and safety.
Development of immunogenic formulations combining chimeric proteins, like E2CD154, fused with the CD154 molecular adjuvant and cyclic di-adenosine monophosphate (cdAMP), for oral immunization, which are administered via attractive baits to induce a potent immune response and protect against CSF and ASF.
The E2CD154 protein combined with cdAMP induces functional neutralizing antibodies and provides early protection against CSFV and ASFV, overcoming previous vaccine limitations by achieving significant immune responses and preventing disease, even in challenging dosing scenarios.
Smart Images

Figure IMGF000027_0001 
Figure 00000029_0000 
Figure 00000029_0001
Abstract
Description
[0001] DESCRIPTIVE MEMORY
[0002] FORMULATION FOR ORAL IMMUNIZATION OF PIGS
[0003] Field of technology
[0004] The present invention relates to the fields of virology, vaccinology, and the biopharmaceutical industry. In particular, it discloses immunogenic formulations that combine one or more chimeric proteins, composed of an immunologically relevant antigen from a pathogenic microorganism of pigs fused to the molecular adjuvant CD154 of pigs, with the adjuvant cyclic adenosine monophosphate (cdAMP) for oral immunization in pigs.
[0005] State of the art
[0006] The development of oral vaccines shows clear advantages over traditional parenteral vaccines. These advantages include lower cost, greater safety and ease of administration and patient adherence, as well as the ability to induce both systemic and mucosal immune responses (Ou B. et al., BioDrugs. 2023 Mar;37(2): 143-180).
[0007] The development of oral vaccines is challenging for two fundamental reasons: 1) immunogenic antigens must be protected from the harsh environment of the digestive tract, and 2) it is difficult to evade the tolerogenic mechanisms associated with protein ingestion. For these reasons, the only effective oral vaccines have been live attenuated vaccines (LAVs), such as the Sabin vaccine for human polio.
[0008] In the field of animal vaccines, particularly those aimed at preventing swine diseases, an oral VVA against Classical Swine Fever (CSF), a highly contagious viral disease with a severe socioeconomic impact on the global swine industry, has also been explored with some success (Ma et al., Genetics and Molecular Res. 2014; 13: 10803-10810). The etiological agent of CSF is the Classical Swine Fever virus (CSFV), a member of the Pestivirus genus of the Flaviviridae family (Simmonds et al., J. Gen. Virol. 2017; 98, 2: 2).
[0009] In this case, oral vaccination is essential for immunizing feral pigs and wild boar, which are important reservoirs of the virus, even in countries where there is no viral circulation in domestic pigs. These wild animals cannot be vaccinated like farm pigs, so other types of vaccines are necessary to protect them from the disease and avoid the risk of the virus spreading to production centers. For these purposes, VVA administered in baits spread throughout the wild boar habitat to be ingested orally by these animals have been used (Milicevic et al., 2013, Veterinary Microbiol. 163: 167-171; Von Rüden et al., Veterinary Microbiology 2008; 132(1-2): 29-38). However, regulatory authorities are increasingly reluctant to release these attenuated viruses into the environment, as they could eventually revert their phenotype and lead to new outbreaks of the disease.Likewise, it has been described that the selective pressure of prolonged use of VVA in these endemic regions selects viral strains of medium or low virulence (Coronado et al., Transboundary and Emerging Diseases 2019; 66: 2362-2382), which originate by recombination or mutations that confer the ability to escape the host's immune response (Hu et al., Frontiers in Microbiology 2016; 7: 85; Ji et al., Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases 2014; 25: 69-77). As a result of this adaptive process, moderate and mild infections are established where clinical symptoms are often masked and it becomes impossible to diagnose the infection, since it is not possible to discriminate between the antibodies produced by the vaccine and those generated by the viral infection.
[0010] Another limitation of oral vaccines based on AAV is their dependence on a cold chain, as these vaccines are thermosensitive and require temperatures between 4°C and 8°C during storage and transportation. Lastly, no less relevant is the fact that catastrophic neutralizing antibodies (CNAbs), transferred by passive immunity from the vaccinated mother to the offspring, interfere with AAV replication and therefore drastically reduce their immunogenicity (Biome et al., Viruses 2017; 9: 86).
[0011] To overcome these difficulties, it is necessary to develop effective subunit vaccines that can be used both in eradication campaigns in endemic regions and in emergency situations in CSF-free regions (Blome et al., Veterinary Microbiology 2017; 206:10-20). Knowledge of the basis of protective immunity against CSFV has led to the development of immunogenic candidates based on protein subunits as an attractive alternative to VAVs for the control and eradication of CSF (Darwich et al., J Gen Virol. 2003; 84: 3453-3457; Dong et al., Vaccine 2007; 25: 205-230). The viral envelope glycoprotein E2 has been the most common choice for inducing a protective response against CSFV (Madera et al., BMC Veterinary Research 2016; 12: 197; Toledo et al., J Biotechnol. 2008; 12: 370-376). These vaccines are safe and induce a potent neutralizing antibody (NAb) response (Barrera et al., Vet Immunol Immunopathol. 2009; 127: 325-331). Additionally, subunit vaccines allow discrimination between infected and vaccinated animals (DIVA) (Dong et al., Vaccine 2007; 25: 205-230). However, the E2-based marker vaccines evaluated to date have only achieved late protection against infection and disease, which is a major disadvantage compared to VVA (Hua et al., PLoS One 2014; 9: e106891; Bouma et al., Vaccine 2000; 18: 1374-1381). These vaccines have also not been successful in preventing vertical transmission of CSFV from infected sows to their offspring, which is another major limitation, since perennially infected sows are born.
[0012] To date, there is no oral subunit vaccine against CSF.
[0013] The CD154 molecule (CD40 ligand) is a glycoprotein of the tumor necrosis factor superfamily. The binding of CD154 on the surface of T cells to its receptor CD40 is essential for promoting and enhancing humoral and cellular immune responses (Hashem et al., J. Immunol. 2014; 193: 722-734). The interaction of CD154 with antigen-presenting cells stimulates increased expression of co-stimulatory and adhesion molecules and upregulation of cytokine secretion (Tralla et al., Eur. J. Immunol. 2016; 46: 420-431). Due to these characteristics, the CD154 molecule has been used as a molecular adjuvant to enhance the immunogenicity of subunit vaccines against different viral infections (Cao et al., Vaccine 2010; 28: 7514-7522; Tang, et al., Cancer Immunol Immunother 2009; 58: 1949-1957).
[0014] In order to overcome the drawbacks of both types of existing vaccines, the chimeric protein E2CD154 was developed by fusing the CSFV E2 glycoprotein and the porcine CD154 antigen (Toledo et al., WO 2007 / 098717 A2). This protein, administered systemically as an emulsion with Montanide ISA50 V2, confers early protection against viral challenge with a highly virulent CSFV strain (Suárez et al., Vaccine 2021; 35(34): 4437-4443; Sordo-Puga et al., Vaccines, 2021; 9, 2: 167) and is capable of preventing vertical transmission (Muñoz-González et al., Vet. Microbiol. 2017; 205: 110-116). However, this same antigen administered orally in repeated high doses in pigs did not generate a detectable immune response, either systemically or in the mucosa.
[0015] Another viral disease that poses a growing threat to the global pork industry is African swine fever (ASF) (Rock DL. Viruses 2021 ; 13(5): 943). Its etiological agent is the African swine fever virus (ASFV), the only known member of the Asfarviridae family.
[0016] Although no proven effective vaccine against this disease has been developed to date, evidence of partial protection has been gathered through immunization with VVA (Chen et al., Sci China Life Sci. 2020;63(5):623-634) or combinations of different ASFV antigens. Among the most promising proteins as immunogenic antigens are the capsid protein p72 and p30, capable of inducing a neutralizing antibody response in pigs (Murgia et al., Archives of Virology, 2019;164:359-370, Kollnberger et al., J Gen Virol. 2002;83:1331-42).
[0017] The ideal oral vaccine against these and other swine pathogens would be a non-replicating subunit vaccine that does not pose any of the risks described above for VVAs. To achieve this, it is necessary to overcome the challenge that non-replicating antigens administered orally generally induce tolerance rather than immunity (Strobel et al., Immunology Today, 1998; 19: 173-181; Zhu and Berzofsky, Gut Microbes 2013; 4: 246-252).
[0018] For these reasons, there is currently no subunit vaccine registered for oral use in humans or animals. The only approved oral vaccines are based on attenuated rotavirus, poliovirus, or inactivated whole Vibrio cholerae bacteria (Marasini et al., Expert Review of Vaccines 2014; 13: 1361–1376).
[0019] Numerous studies have been conducted in animal models with the aim of developing adjuvants capable of promoting a more efficient response against protein antigens administered through the mucosa. Among the effects sought with these adjuvants, vehicles, or immunomodulators are: 1) protecting immunogenic antigens from the action of proteases during their passage through the digestive tract; 2) facilitating the adhesion of these antigens to the mucosa; and 3) stimulating immune system receptors to induce an effective immune response. Among the compounds evaluated as adjuvants we have bacterial toxins and their derivatives (Pizza et al., Vaccine. 2001; 19 (17-19): 2534-2541; Inskeep TK, et al., Clin Vaccine Immunol. 2010; 17(8): 1163-1169; McCluskie et al., Vaccine, 2000; 19: 950-957) and oligonucleotides containing CpG motifs (McCluskie et al., Vaccine 2000; 19: 950-957), among others.The encapsulation of antigens in nanoparticles composed of compounds of diverse chemical nature has also been tested (Minato et al., Journal of Controlled Release 2003; 89: 189-197; Rezaei et al., Biomaterials Science 2021; 9: 2679-2695; Tian et al., International Immunopharmacology 2008; 8: 900-908; Salman et al., Vaccine, 2009; 27: 4784-4790; Slütter et al., Journal of Controlled Release 2009; 138: 113-121; Jain et al., International Journal of Pharmaceutics 2010; 387: 253-262; Sarti et al., Biomaterials 2011; 32: 4052-4057). However, despite promising results in mouse models, these formulations have not been converted into useful products for humans or animals.
[0020] One of the adjuvants that has been successfully used to enhance the immune response against different antigens, both systemically and mucosally, are the so-called cyclic dinucleotides (CDN) (Ebensen et al., Clin. Vac. Immunol. 2007; 14 (2007) 952-958; Ebensen et al., Frontiers in Immunology 2017; 8:1223) and in particular cyclic di-adenosine monophosphate (cdAMP) (c-di-AMP: Bis-(3',5')-cyclic dimeric adenosine monophosphate) (Ebensen et al., Vaccine 2011; 29 (32): 5210-5220). These molecules of bacterial origin function as agonists of Sting (stimulator of interferon genes) receptors, which mediate the activation of different cellular processes related to the secretion of type 1 interferons in cells of the immune system (Yan, H. & Chen, W. Vaccines 2021; 9: 917). However, most of these experiments have been conducted in mice, a model very far removed from larger animal species, such as pigs or humans.For this reason, it is not possible to automatically extrapolate the results from one species to another. The combination of cyclic guanosine di-monophosphate (cdGMP) (cGAMP: 2'3'- cyclic guanosine monophosphate-adenosine monophosphate) with inactivated influenza virus led to an increase in the antibody response when administered intradermally (ID) in pigs (Wang et al., 2016, Journal of Investigative Dermatology 136(11): 2183-2191). The addition of cdGMP together with trehalose 6,6'-dibenzene (TDB), a Minele receptor agonist, significantly increased the antibody response against a mixture of foot-and-mouth disease virus antigens further adjuvanted with AIOH and Quil A in pigs, but in this case the immunogen was administered by the intramuscular route (Lee et al., Frontiers in Immunology 2019; 10: 2509).
[0021] The addition of cdAMP increased both antibody and T cell responses in combination with Mycoplasma hyopneumoniae bacterins administered by the intradermal (ID) route in pigs (Matthijs et al., 2019, Frontiers in Immunology 10: 1087). Also via the ID route, the combination of cdAMP with 70–80 nm nanoparticles increased both humoral and cellular responses in pigs against ovalbumin.
[0022] However, none of these investigations verified the functionality of the immune response induced by these immunogens, which is a major limitation. Furthermore, the addition of cdAMP to an influenza peptide administered intravenously to pigs induced low levels of antibodies but was unable to protect the animals from challenge with a pathogenic strain. This indicates that the antibodies generated were not functional; on the contrary, the post-challenge viral load was higher in vaccinated animals than in controls, so the effect obtained was the opposite of the desired one (López-Serrano et al., Vaccines 2021;9: 751).
[0023] The only attempt to use CDM (CDM: cross-linked dextran microspheres) as an adjuvant via the nasal route in pigs by mixing it with virus-like particles of porcine reproductive and respiratory syndrome virus (PRRSV) not only failed to break tolerance, as no antibodies against the virus were detected, but also induced a state of increased susceptibility of the animals to a challenge with a pathogenic strain (Van Noort et al., Virology Journal 2017; 14:1-9).
[0024] The results listed indicate that oral immunization of pigs with subunit vaccines is an unsolved problem, and that experiments conducted in mice, or using other immunization routes, are not automatically extrapolated to immunization by the oral route in this species.
[0025] Explanation of the invention
[0026] The present invention is directed at solving the problem posed by the lack of subunit vaccines that are effective when administered orally to pigs. This application shows examples of oral formulations against CSF and ASF, although it is not limited to these diseases, as the immunogenic formulations disclosed can also be used against other swine pathogens.
[0027] In their most general approach, these immunogenic formulations comprise one or more chimeric proteins formed by i) an immunologically relevant antigen of a pathogenic microorganism of pigs fused to the molecular adjuvant CD154 of pigs and i) an adjuvant selected from the family of di-cyclic nucleotide monophosphates, for the oral immunization of pigs. One of the embodiments of the invention is the combination of the E2CD154 antigen, formed by the fusion between the E2 protein of the CSF virus and the porcine CD154 molecule (SEQ ID NO: 1), with the adjuvant d¡-Cyclic Adenosine Monophosphate (cdAMP), and this combination is administered to the pigs orally, either in solution, encapsulated in nanoparticles, or together with a pharmaceutically acceptable excipient.
[0028] In particular, the invention relates to the administration of this mixture of E2CD154 and cdAMP to pigs through a bait, which can be based on different types of food such as rice, wheat flour, corn, or other cereals, in such a way that it is attractive for consumption by wild animals.
[0029] The present invention demonstrates that the E2CD154 protein, identified as SEQ ID NO: 1, is surprisingly capable of inducing a potent immune response via the oral route in mice when combined with the cdAMP adjuvant.
[0030] In the first example of the present invention, the immunogenicity of the combination of the protein identified as SEQ ID NO: 1 and the cdAMP adjuvant administered orally to mice is demonstrated. This immune response was characterized by the appearance of specific antibodies in serum. It was also demonstrated that these antibodies are functional, since they are capable of neutralizing the replication of the CSF virus with titers greater than 1:50 in a peroxidase-linked neutralization assay (PLNA).
[0031] Example 2 of the present invention also demonstrates that this combination of cdAMP and the molecular adjuvant CD154 is the key to achieving a potent humoral response against the vaccine antigen. Both immunomodulatory elements act synergistically, since the combination of the E2 protein without CD154 with cdAMP fails to induce the same antibody response in mice, either in frequency or in the antibody titers achieved.
[0032] Example 3 illustrates how a formulation comprising the protein identified as SEQ ID NO: 1 and cdAMP, administered orally, induced the appearance of specific antibodies against the E2 protein in the serum of pigs, and these antibodies in turn were able to neutralize the replication of CSFV in an NPLA assay with titers of 1:12.5 and 1:25.
[0033] In example number 4 of the present invention it is also evident that, surprisingly, the oral administration of the formulation described in the present invention was able to protect these pigs from a lethal challenge with the highly virulent strain "Margarita", belonging to subgenotype 1,4 of the CSF virus. This result is unexpected and contrasts with previous experiments described in the literature, where other authors had not only not found any protective effect after immunization with formulations containing this type of adjuvant, but, on the contrary, its administration had increased the susceptibility of the animals to infection (Van Noort et al., 2017, Virology Journal 14:1-9).Three of four animals vaccinated with the highest doses of E2CD154 and cdAMP did not become ill or develop fever, while unvaccinated controls showed various clinical signs of the disease, including fever starting on day 12 post-challenge (dpr) and had to be sacrificed at 18 and 20 dpr. These results demonstrate the protective nature of the immunogenic formulation of the present invention in the target species. A dose-response relationship is also demonstrated, since the formulation with the highest amounts of E2CD154 and cdAMP conferred a better immune response and better protection in pigs than the formulation with lower doses. In the examples presented in this invention, cdAMP was used, but it is evident to anyone versed in the state of the art that other CDNs, such as cdGMP or cdGAMP, which are also STING receptor agonists, can have similar effects as immunopotentiators.
[0034] In one embodiment of the invention, immunogenic compositions comprising the protein identified as SEQ ID NO: 1 and the cdAMP adjuvant are administered to pigs by means of a bait. The efficacy of this form of administration is illustrated in Example 5, where a rice-based bait is used, but it is evident to anyone skilled in the art that baits constructed from different foods attractive to pigs, such as wheat, corn, or other cereals, can be used with similar results.
[0035] Example 6 shows the results of the viral challenge, which shows that the pigs in the previous example, immunized with bait, are protected against CSF.
[0036] The present invention also shows that the synergistic combination of the molecular antigen CD154 with the cdAMP adjuvant can be used for the development of oral vaccines against other pathogens.
[0037] Example 7 shows how an immunogenic formulation formed by one or two ASFV proteins (p72t and p30) fused to CD154 (SEQ ID NO: 2 and SEQ ID NO: 3), in combination with cdAMP, achieves a better immune response, both humoral and cellular, against ASFV when administered orally, compared to the p72t protein without CD154 combined with cdAMP, or the same proteins administered in the absence of cdAMP. It is shown that the antibodies generated neutralize ASFV replication in vitro and that animals vaccinated with these formulations combined with cdAMP are protected from the disease when challenged with a virulent strain of ASFV.
[0038] Brief description of the figures
[0039] Figure 1. Weight of animals immunized orally with the E2CD154 / cdAMP combination and controls that received only E2CD154 or PBS. Triangles: group 1, PBS negative control; circles: group 2, E2CD154; squares: group 3, E2CD154 + cdAMP. Figure 2. Anti-E2CD154 titers measured by indirect ELISA in mouse serum after two and three doses. Titers are expressed as the reciprocal of the last serum dilution to give a positive signal in the ELISA (2 times the value of the negative control). Group 1, PBS negative control; group 2, E2CD154; group 3, E2CD154 + cdAMP.
[0040] Figure 3. Anti-E2CD154 neutralizing antibody titers in mouse serum after two and three doses. Group 1, PBS negative control; group 2, E2CD154; group 3, E2CD154 + cdAMP.
[0041] Figure 4. Anti-E2CD154 antibody response measured by indirect ELISA in immunized mice after three doses. 1) Group 1: E2 + cdAMP; group 2: E2CD154 + cdAMP; group 3: E2; group 4: E2CD154; group 5: negative controls. There are significant differences between the titers of group 2 and the rest (Kruskal Wallis, Dunn, p<0.05).
[0042] Figure 5. E2-specific antibodies in the serum of immunized pigs are measured by competitive ELISA (PrioCHECK CSFV Ab2.0, Thermo Fischer, USA) after the fourth dose. 1) Group 1: pigs immunized with lower doses of E2CD154 and cdAMP; 2) Group 2: pigs immunized with higher doses of E2CD154 and cdAMP; 3) Group 3: negative controls.
[0043] Figure 6. Anti-E2CD154 antibody response measured by indirect ELISA in immunized pigs after four doses. 1) Group 1: pigs immunized with the lower doses of E2CD154 and cdAMP; 2) Group 2: pigs immunized with the higher doses of E2CD154 and cdAMP; 3) Group 3: negative controls.
[0044] Figure 7. Weight of vaccinated and control pigs after challenge. 1) Group 1. Immunized with lower doses of E2CD154 and cdAMP; 2) Group 2, immunized with higher doses of E2CD154 and cdAMP; 3) Group 3, negative controls.
[0045] Figure 8. Time course of rectal temperature in pigs challenged with CFPV.
[0046] A. Average rectal temperatures by group; B. Group 3: controls; C. Group 1: immunized with lower doses of E2CD154 and cdAMP; D. Group 2: immunized with higher doses of E2CD154 and cdAMP. Figure 9. Time course of clinical scores in pigs challenged with CSFV. A. Group 1: immunized with lower doses of E2CD154 and cdAMP; B. Group 2: immunized with higher doses of E2CD154 and cdAMP; C. Group 3: negative controls. Figure 10. Time course of clinical scores in pigs challenged with CSFV. A. Group 1: pigs immunized with baits containing only cdAMP; B: Group 2: immunized with baits containing E2CD154 and cdAMP.
[0047] Figure 11: Total IgG titers specific to the ASFV p72t antigen measured by indirect ELISA. Titers are expressed as the Iog2 of the reciprocal of the last dilution at which the OD at 450 nm of the test sera in the ELISA was twice the OD of the pre-immune sera. The value represented for each group corresponds to the geometric mean calculated from the titers obtained for each animal within each experimental group. From day 14, statistically significant differences were found between the titers of groups G2 and G6 with respect to the rest by means of a Kruskal Wallis test followed by Dunn's multiple test (P<0.05).
[0048] Figure 12: Total IgG titers specific to the ASFV p30 antigen measured by indirect ELISA. Titers are expressed as the 1µg of the reciprocal of the last dilution at which the OD at 450 nm of the test sera in the ELISA was twice the OD of the preimmune sera.
[0049] Figure 13: Neutralization of ASFV-G infection by serum from animals immunized with different ASF immunogenic candidates. The ASFV-G strain was incubated with preimmune sera (white bars) or immune sera (black bars) from the different experimental groups and then infected Vero cells. After 16 hours, the percentage of p72 expression was determined by FACS using a specific mAb antibody against p72. The p72 expression of Vero cells infected with ASFV-G preincubated with preimmune sera was considered as 100% from which the % p72 expression of Vero cells infected with ASFV-G preincubated with immune sera was calculated.
[0050] Figure 14: Induction of IFN-gamma-producing cells specific for ASFV antigens. The number of IFN-gamma-secreting cells is shown after in vitro re-stimulation with p73t and p30 antigens from PBMCs of immunized and control animals, 7 and 42 days after the first immunization (7 days post-challenge). Data represent the mean per group and the standard deviation is represented by the bars pointing in the positive direction. Asterisks represent statistically significant differences with respect to the control group (ANOVA followed by a Bonferroni multiple comparisons test, (*) p < 0.05; (**) p < 0.001).
[0051] Figure 15: Challenge of immunized and control pigs with the highly virulent ASFV-G strain. The challenge took place on day 35 after the first immunization with 10 4HAD50 of the ASFV-G strain administered intranasally. (A) Daily rectal temperature of pigs in each experimental group after viral challenge. Fever was defined as a rectal temperature above 40°C for two or more consecutive days. The points represent the mean temperature per group, and the standard deviation is represented by bars in both directions. (B) Clinical score of pigs in each experimental group after viral challenge.
[0052] Detailed description of implementation methods / Examples of implementation
[0053] Example 1. Immunization of mice by the oral route with the protein identified as SEQ ID NO: 1 in combination with cdAMP.
[0054] The E2-CD154 protein, identified as SEQ ID NO: 2, was obtained from the HEK 293 cell line, which contains the integrated gene encoding this protein (SEQ ID NO: 1). Cells were cultured in a 10 L BIOSTAT B Plus thermoregulator (Germany) with serum-free medium. The metabolized culture medium was concentrated in a tangential flow concentrator (PESU 100 kDa cassette, Sartorius, Germany) to an approximate concentration of 0.2 mg / ml and filtered through a 0.2 pM capsule. It was stored at 4°C until use.
[0055] 1.6 mg of cdAMP (Jenna Bioscience, Germany) was weighed and resuspended in 200 pl of type II H2O for a concentration of 8 mg / ml. Aliquots of 10 pl were made and frozen at -20°C until use.
[0056] BALB / c mice weighing between 18 and 22 g were immunized (CENPALAB). Animals were weighed on day 0 and after each dose. They were divided into 3 groups of 5 mice each. Group 1 received phosphate-buffered saline (PBS) orally, group 2 received 50 mM E2CD154 in phosphate buffer + 0.5 M NaCl, pH 7.2, and group 3 was immunized with E2CD154 + cdAMP. Mice were immunized on days 0 and 7, blood was drawn on day 15, and a third dose was administered on day 17. The last blood draw was performed on day 24. The first dose consisted of 25 pg of E2CD154 and 16 pg of cdAMP administered sublingually. In doses 2 and 3, 2.5 pg of E2CD154 and 5 pg of cdAMP were administered by the same route in a volume of 20 pl.
[0057] To evaluate the presence of anti-E2CD154 antibodies in the serum of inoculated mice, an indirect ELISA was performed, for which Maxisorp plates (Thermo Fisher Scientific, USA) were coated with 5 pg / ml of E2CD154 (Lot 2117). The sample was blocked for 1 h with PBS 1% milk and then at 37°C, and serum samples were added at a 1:40 and 1:80 dilution in PBS 1% milk + 0.05% tween 20. Serum from a mouse immunized intramuscularly with the Porvac® vaccine was used as a positive control, and unvaccinated mouse serum was used as a negative control. Sera were incubated for 1 h at 37°C. The plates were washed twice with PBS + 0.05% tween 20 and a 1:5000 dilution of an anti-mouse immunoglobulin-peroxidase conjugate (Sigma, USA) was added. After 1 h of incubation at 37°C, the plates were washed and the chromogenic substrate (Tetramethyl benzidine, TMB with H2O2) was added. The reaction was stopped with stop solution (40.2 M H2SO4) after 10 min and read in an ELISA plate reader at 450 nM.Sera with optical density (OD) values two or more times higher than the negative control were considered positive and were titrated using twofold signal dilutions. The titer was defined as the last serum dilution with an OD two times higher than the negative control serum at the same dilution.
[0058] Figure 1 shows that mice immunized with the E2CD154 and cdAMP combination experienced similar weight gain to control mice. No statistically significant differences were found between the animals that received PBS or the E2CD154 group (Student's t test, p>0.05). Administration of the immunogen was well tolerated. No other adverse effects were observed in the vaccinated animals.
[0059] Figure 2 shows the E2CD154 antibody titers of individual mice measured by ELISA after two and three doses. After the second dose, five of six mice in the group receiving the E2CD154 / cdAMP combination seroconverted, whereas the control group and the two animals tested in the E2CD154 group did not develop E2CD154 antibodies.
[0060] After the third dose, all six mice immunized with the E2CD154 and cdAMP mixture had developed antibodies. The geometric mean titers increased to 12,800, significantly higher than those measured after two doses (Student's t test, p = 0.0197). Only two of five mice in the group immunized with E2CD154 alone seroconverted, and with titers significantly lower than those in the combined E2CD154-cdAMP group (Student's t test, p = 0.0068). The titer data in these groups passed the Kolmogorov-Smirnov normality test.
[0061] The ability of the generated antibodies to neutralize CSFV replication was assessed by NPLA. This technique was developed according to OIE recommendations and as described in previous publications (Santana et al., Int. J Sci. Res. Biol. Sciences 9, 2: 30-34, 2022). Four of the six mice that responded to the E2CD154 / cdAMP combination showed serum Ab titers above 1:50 (Figure 6). Titers above this value are considered protective in pigs. In the remaining groups, no mice showed neutralizing titers.
[0062] Example 2. Comparison between the immunogenicity of E2 and E2CD154 together with oral cdAMP in mice
[0063] In order to evaluate the contribution of the cdAMP and CD154 adjuvant to the immunogenicity of the oral formulation tested, BALB / c mice weighing between 18 and 20 g were immunized with the E2 or E2CD154 proteins, with and without cdAMP. The following experimental groups were formed, each with 5 animals: group 1: 2.5 pg of E2 + 5 pg of cdAMP; group 2: 2.5 pg of E2CD154 + 5 pg of cdAMP; group 3: 2.5 pg of E2; group 4: 2.5 pg of E2CD154; group 5: 5 pg of cdAMP (negative control). The antigen-adjuvant mixture was formulated in sodium phosphate buffer pH 7.2 + 0.5 M NaCl. Immunogens were administered orally in a volume of 20 pl on days 0, 7 and 14. The presence of specific antibodies against E2 in the serum of the mice was evaluated by an indirect ELISA described in example 1, 7 days after the last immunization.As observed in Figure 4, the best antibody response against E2CD154, both in response frequency (100%) and in the obtained titers, was found in the group that received the combination of E2CD154 with cdAMP. Only one of the 5 mice evaluated seroconverted in the groups immunized with E2-cdAMP or E2CD154 (groups 1 and 4, respectively). In these two groups, the neutralizing titers were much lower than those of group 2. The differences between the titers of group 2 and the rest of the groups were statistically significant, according to the Kruskal Wallis test and the Dunn's multiple comparison test for p < 0.05. On the other hand, none of the five mice evaluated in the group that received the E2 protein without adjuvant showed detectable antibodies against E2 (group 3). Furthermore, mice immunized only with cdAMP also tested negative (group 5).
[0064] These results demonstrate the synergistic effect of combining the molecular adjuvant CD154 with cdAMP, which enhances the immunogenicity of the orally administered E2 protein, something that cannot be observed when either component is administered separately. A significant response level was not achieved in any case.
[0065] Example 3. Immunization of pigs by the oral route with the protein identified as SEQ ID NO: 1 in combination with cdAMP
[0066] The E2CD154 protein and cdAMP were used as described in Example 1. Duroc / Yorkshire hybrid pigs weighing between 9 and 11 kg (CENPALAB) were used.
[0067] Pigs received 4 immunizations on days 0, 7, 21 and 28 by spraying into the oral cavity as follows: Group 1, doses 1 and 2: 100 pg of E2CD154 + 50 pg of cdAMP in 0.75 ml of 50 mM phosphate buffer + 0.5 M NaCl, pH 7.2; doses 3 and 4: 100 pg of E2CD154 + 200 pg of cdAMP in 0.75 ml of 50 mM phosphate buffer + 0.5 M NaCl, pH 7.2; Group 2, doses 1 and 2: 500 pg of E2CD154 + 50 pg of cdAMP in 3.6 ml of 50 mM phosphate buffer + 0.5 M NaCl, pH 7.2, doses 3 and 4: 500 pg of E2CD154 + 400 pg of cdAMP in 3.6 ml of 50 mM phosphate buffer + 0.5 M NaCl, pH 7.2; Group 3: control with 1 ml of PBS. Blood was drawn on days 15, 28 and 34 from the ophthalmic orbital sinus. Serum was separated and stored at -20°C until use.
[0068] The presence of anti-E2CD154 antibodies in pig serum was evaluated using two different ELISA formats: 1) the PrioCHECK CSFV Ab2.0 competitive ELISA (Thermo Fischer, USA) according to the manufacturer's recommendations; and 2) an indirect ELISA developed in our laboratory. The criteria for serum positivity were an inhibition index equal to or greater than 40% or an optical density twice as high as the negative control, respectively.
[0069] Figure 5 shows the E2CD154 Ab titers of individual pigs after four doses as measured by the PrioCHECK CSFV Ab2.0 competitive ELISA. After the fourth dose, two of the four pigs in group 2, which received the highest dose of the E2CD154 / cdAMP combination, had seroconverted, whereas the control group and the group receiving the lower dose did not develop antibodies to E2CD154.
[0070] Indirect ELISA was performed on Polysorp plates (Thermo Fisher, USA) coated with 5 pg / ml of E2CD154 (Lot 2117). The plates were blocked for 1 h with 1% milk PBS at 37°C, and two-fold serial dilutions of sera were added, starting at 1:200 in 1% milk PBS + 0.5% tween 20. Serum from a pig immunized intramuscularly with the Porvac® vaccine with a neutralizing titer of 1:50 was used as a positive control, and serum from an unvaccinated pig was used as a negative control. Sera were incubated for 1 h at 37°C. The plates were washed twice with PBS + 0.05% tween 20, and a 1:10,000 dilution of an anti-pig IgG peroxidase conjugate (Sigma, USA) was added. After 1 h of incubation at 37°C, the plates were washed, and the substrate (TMB with H2O2) was added. The reaction was stopped with stop solution after 5 min and read in an ELISA plate reader at 450 nM. The assay blank (wells without serum) was subtracted from the optical density (OD) values of the serum.Dilutions with an OD value 2 or more times higher than the negative control and above 0.1 were considered positive. The titer was defined as the last serum dilution with an OD greater than 0.1 and twice as high as the negative control serum at the same dilution.
[0071] Figure 6 shows the E2CD154 Ab titers of individual pigs after four doses measured by indirect ELISA.
[0072] After the fourth dose, three of the four pigs immunized with the mixture of E2CD154 and cdAMP had seroconverted. The two sera positive in the competitive ELISA showed the highest titers. In addition, one of the four pigs in group 1 also seroconverted with a titer of 1:800. The two pigs in the control group did not develop antibodies against E2CD154.
[0073] The presence of neutralizing antibodies to the infection was evaluated by the NPLA assay performed according to the aforementioned procedure (Santana et al., Int. J. Sci. Res. Biol. Sciences 2022; 9, 2: 30-34). The 2 sera positive in the competitive ELISA and with higher titers in the indirect ELISA, showed a neutralizing titer of 1 :12.5 and 1 :25 in this assay.
[0074] Example 4. Protection of vaccinated pigs against challenge with a highly pathogenic strain of CSFV
[0075] The pigs immunized in the previous example were challenged at 34 days post vaccination (7 days after the last dose) by the intranasal route with 2 x 10 3DLso of the "Margarita" strain of CSFV. One of the animals in group 1 was not challenged because it suffered an accident during transportation to the challenge area, and it was decided to exclude it from the study. The clinical status of the animals was monitored daily after the challenge. The clinical score for signs of swine fever was calculated according to the formula proposed by Mittelholzer (Mittelholzer et al. Vet. Microbiol. 2000; 74: 293-308).
[0076] Animals vaccinated with the higher doses (group 2) maintained a tendency to gain weight during the 21 days after the challenge, while those with the lower dose (group 1) began to lose weight from day 14, and the controls (group 3) experienced a very low weight gain until their sacrifice at 14 days post-challenge (dpr) (Figure 7).
[0077] Figure 8 shows the time course of rectal temperature in the days following challenge. A rectal temperature above 40.3°C for two consecutive days was considered fever. Figure 8A shows that the average temperature increased from 12 dpr in the controls, and Figure 8B shows that the two pigs in this group developed fever at 12 dpr and remained so until slaughter at 18 and 20 dpr (Figure 8B). In the group immunized with the lower doses of E2CD154 and cdAMP, an increase in temperature was observed in one pig from day 14 and in another from day 18, which reached sustained fever (Figure 8C). The other pig in the group did not experience an increase in rectal temperature. However, in group 3 vaccinated with the highest doses of ECD154 and cdAMP, only one of the animals showed an increase in temperature with sustained fever from 18 dpr.
[0078] Figure 9 shows the clinical scores of the animals after challenge. Control animals began to develop clinical signs of the disease from 12 dpr and were sacrificed on day 18 (Figure 9C). Two of the three pigs vaccinated with the lowest dose showed signs of CSF, one from day 15 and the other on day 20. These animals were sacrificed at 18 and 20 dpr due to presenting clinical signs of advanced CSF (Figure 9A). The third animal in this group remained free of signs of CSF. Meanwhile, of the four animals immunized with the highest dose, only one showed clinical signs of CSF from day 19 and was sacrificed on day 20 (Figure 9B). This 579 animal was the only one that had not developed an antibody response against E2CD on the day of challenge, indicating a correlation between the presence of specific antibodies in serum (even with modest titers) and protection against challenge.
[0079] Example 5. Oral immunization of pigs with E2CD154 supplied orally in baits.
[0080] To evaluate a formulation and delivery method for the immunogen closer to that expected to be used in a vaccine for wild pigs, baits were prepared with cooked rice. The E2CD154 protein was lyophilized, mixed with cdAMP, and enclosed in biodegradable capsules at a ratio of 500 pg of E2CD154 and 500 pg of cdAMP per capsule. Each capsule was coated with cooked rice paste to form spherical baits with an approximate diameter of 4 cm. The ability of these baits to induce a specific neutralizing antibody response against CSFV was evaluated in Duroc / Yorkshire hybrid pigs weighing 9–11 kg (CENPALAB). The animals were individualized in paddocks, and the baits were administered on an empty stomach for 3 consecutive days, one bait per animal. The consumption of the baits by the animals was monitored by permanent visual observation during the first 4 hours.This procedure was repeated for 3 consecutive weeks, and in the fourth week, blood was extracted from the animals to evaluate the presence of AcN in the serum using the NPLA technique, as described in Example 1 of the present invention. Four pigs were immunized with the immunogenic formulation and another two animals received baits that only contained the cdAMP adjuvant.
[0081] Three of the four pigs that received the immunogenic formulation developed neutralizing antibody titers against CSFV, with titers of 1:25 (pig 670) and 1:50 (pigs 671 and 673). In the fourth animal, the Ab titers were lower than 1:12.5 (pig 672). In contrast, none of the animals in the control group developed Ab against CSFV. These results demonstrate that controlled administration of the E2CD154-cdAMP combination in a bait is capable of inducing Ab against CSFV.
[0082] Example 6. Protection of pigs vaccinated with the E2CD154-cdAMP combination formulated in rice baits against CSFV challenge
[0083] The immunized pigs in the previous example were challenged intranasally with 2 x 10 3 DLso of the Margarita strain of CSFV. The clinical status of the animals was monitored daily after the challenge. The clinical score for signs of swine fever was calculated according to the formula proposed by Mittelholzer (Mittelholzer et al., Vet. Microbiol. 2000; 74: 293-308).
[0084] Figure 10 shows the clinical scores of the animals after challenge. Control animals began to develop clinical signs of the disease from 11 dpr and were sacrificed on day 17 (Figure 10A). In contrast, only one of the four vaccinated pigs showed signs of CSF from day 16 and was sacrificed at 22 dpr due to presenting clinical signs of advanced CSF (Figure 10B). This 672nd animal was the only one that had not developed an AbN response against E2CD154 on the day of challenge, confirming the correlation between the presence of specific antibodies in serum and protection after challenge. The remaining three pigs that showed AbN against CSF on the day of challenge did not show any clinical signs of the disease until the end of the trial. The results demonstrate that protection in pigs can be achieved with the E2CD154 + cdAMP combination when administered as baits via oral vial.
[0085] Example 7. Oral immunization of pigs with a formulation of the African swine fever virus antigens identified with SEQ ID NO:2 and SEQ ID NO:3 in combination with cdAMP. In order to evaluate the humoral and cellular response generated by vaccine candidates against the African swine fever virus (ASFV), nine-week-old Duroc / Yorkshire crossbred pigs between 25-30 kg, negative for CSF and ASF, were immunized with different formulations. The animals were fed 2 kg / per animal / per day of commercial feed (CENPALAB, Cuba) and water ad libitum. All experimental procedures were carried out according to the guidelines and procedures for the use of laboratory animals. The selected antigens were the ASF virus p72t and p30 proteins, which were tested alone and fused to pig CD154 (p72t-CD154, SEQ ID NO:2 and p30-CD154, SEQ ID NO:3). The experimental groups were as follows:
[0086] Group (5 animals): Non-immunized controls
[0087] Group 2 (5 animals): Immunized orally with four doses of 500 pg of the p72t-CD154 protein + 400 pg cdAMP on days 0, 7, 21 and 28 in a total volume of 1 ml of PBS. Group 3 (5 animals): Immunized orally with four doses of 500 pg of the p72t-CD154 protein on days 0, 7, 21 and 28 in a total volume of 1 ml of PBS.
[0088] Group 4 (5 animals): Immunized orally with four doses of 500 pg of the p72t protein + 400 pg cdAMP on days 0, 7, 21 and 28 in a total volume of 1 ml of PBS.
[0089] Group 5 (5 animals): Immunized orally with four doses of 500 pg of the p72t protein on days 0, 7, 21 and 28 in a total volume of 1 ml of PBS.
[0090] Group 6 (5 animals): Immunized orally with four doses of 500 pg of the p72t-CD154 and p30-CD154 proteins + 400 pg of cdAMP in 1 ml of PBS on days 0, 7, 21 and 28.
[0091] Blood was drawn from the animals every 7 days to determine antibody titers. The total IgG titer specific for the viral antigens p72t and p30 was determined using an indirect ELISA developed in our laboratory. To do this, High binding plates (Costar, USA) were coated with 100 pl of p72t or p30 at a concentration of 10 pg / ml overnight at 4°C. Four washes with PBS-0.05% Tween 20 were then performed. These plates were blocked with 3% skim milk in PBS for 1 h at 37°C, and then 100 pl of two-fold serial dilutions in PBS of the study sera, previously inactivated at 56°C for 30 minutes, were applied, starting with a dilution of 1:500 up to 1:64,000. The plates were incubated at 37°C for 1 h and then washed four times with PBS-0.05% Tween 20. Subsequently, 100 pl of a 1:10,000 dilution of a peroxidase-conjugated anti-pig IgG antibody (Sigma, USA) was added.The plates were incubated again at 37°C for 1 h. After 4 washes under the same conditions as above, the reactions were revealed using a substrate solution with 0.1% tetramethylbenzidine (TMB, 1 mg / ml in DMSO) in 0.1 M citric acid and 0.2 M Na2HPO4, pH 5 and 0.006% hydrogen peroxide, for 10 min at room temperature. After stopping the reaction with 50 pl of 2 M H2SO4, the absorbances of the wells were measured at a wavelength of 450 nm in a plate reader (SUMA, Immunoassay Center, Cuba). The sample titer was defined as the serum dilution where the absorbance was greater than or equal to twice the absorbance of the pre-immune serum.
[0092] Antibody titers against p72t were only observed when the antigen was the chimeric protein p72t-CD154 combined with cdAMP, regardless of whether it was combined with p30-CD154 (groups 2 and 6). There were no differences in anti-p72t IgG titers between these two groups (Figure 11).
[0093] Animals in group 6 also developed specific IgG titers against p30 from day 14 (Figure 12).
[0094] The neutralizing capacity of these antibodies against the ASF virus was assayed by FACS (Fluorescence Activating Cell Sorting). To do this, monolayers of Vero cells cultured in DMEM (Dulbecco's modified Eagle's medium) medium with 5% (v / v) fetal bovine serum and gentamicin at 100 pg / ml were infected at an MOI of 1 using a viral strain multiplied in these cells with a passage number < 15 derived from the highly virulent parental virus of the Georgia / 2007 isolate (ASFV-G). This viral strain was previously incubated for 18 h at 37°C with a 1 / 5 dilution of pre-immune or immune sera on the day of challenge, respectively.The percentage of cells expressing the major viral capsid protein p72t was determined 16 h post-infection using a 1:10 dilution of a monoclonal antibody against this protein conjugated to FITC by flow cytometry on a CyFlow Space Cytometer (Partee) equipped with FloMax® software. Each sample was assayed in duplicate. Vero cells without the addition of the conjugated mAb were used as unlabeled controls to determine the baseline autoflorescence signal of the samples. Analysis of the acquired data was performed using FlowJo v.10 software (FlowJo LLC, Tree Star). Statistical analysis of the percentages was performed using GraphPad Pñsm version 8.0 software (GraphPad Software).
[0095] As seen in Figure 13, the highest percentages of inhibition of p72t expression by Vero cells infected with ASF virus were obtained when CD154 and cdAMP were included together with the antigens in the vaccination.
[0096] For cellular response studies, peripheral blood mononuclear cells (PBMCs) were isolated from three animals from each group by Ficoll centrifugation (GE Healthcare Life Sciences) seven days after the initial immunization and seven days after challenge and resuspended in RPMI 1640 medium supplemented with 1X antibiotic / antimycotic solution and 10% fetal bovine serum. Antigen-specific IFN-γ response was determined by a BASIC porcine IFN-γ ELISpot assay (MABTECH). The assay was performed using 96-well plates according to the manufacturer's instructions. Briefly, plates were coated overnight at 4°C with 100 pL of the anti-IFN-γ capture antibody prepared at 10 pg / ml. The plates were then washed five times with 200 pl of sterile PBS and blocked with culture medium for 2 h at 37°C. 5 x 10 were then added to each well. 5PBMC from each sample in triplicate were previously mixed with 5 pg / ml of the p72t and p30 proteins. As controls, cells were added in the absence of virus (negative control), or cells mixed with the mitogen concanavalin A (Con A) at 6 pg / ml as a positive control. After 36 h of incubation at 37°C, the plates were washed 5 times with 200 µl per well of PBS and then the biotinylated anti-IFN-γ detection antibody (P2C11) was added at 0.5 pg / ml in PBS + 0.5% FBS for 2 h at room temperature. Subsequently, the plates were washed and streptavidin-ALP diluted 1:1000 in PBS with 0.5% FBS was added. After a 1-h incubation at room temperature, the plates were washed again with PBS and developed with 100 µl of BCIP / NBT substrate (Mabtech, cat. # 3650-10) per well for 30 min. The reaction was stopped by washing the plate with hard water. The plates were allowed to dry overnight, and the spots were counted.To calculate the number of antigen-specific IFN gamma-producing cells in each sample, the number of spots obtained in PBMCs stimulated with viral proteins was subtracted from the number of spots obtained in the absence of these proteins.
[0097] The results showed that seven days after challenge, a significant stimulation of IFN gamma production was evident compared to the control group only in those groups in which the PPA antigens were combined with CD154 and cdAMP. In the case of the group immunized with the p72t-CD154 chimera combined with p30-CD154 and cdAMP, the stimulation of IFN gamma production was significantly higher than in the group immunized with the p72t-CD154 chimera and cdAMP (Figure 14).
[0098] The challenge of all experimental groups was carried out under biosafety level 3 containment conditions. The pigs were inoculated 7 days after the last immunization, instilling 1 ml containing 10 4 HADso (median hemadsorption units) of the ASFV-G strain were administered intranasally. Rectal temperature was recorded daily for 20 days after challenge, as were clinical signs such as anorexia, depression, purple skin discoloration, wobbly gait, diarrhea, and cough. Samples (blood and oral swabs) were collected on days 2, 4, 8, 16, and 28 post-inoculation. These samples were used to detect the presence of the virus using qPCR. In parallel, viral replication was detected in Vero cell cultures using flow cytometry, as previously described.
[0099] From the fourth day post-challenge, animals in the control group developed clinical signs compatible with ASF, such as fever with temperatures above 41 °C (Figure 14A), anorexia, and ataxia. From the sixth day of viral challenge, a clear deterioration in animal health was observed, including diarrhea, conjunctivitis, respiratory disorders, severe prostration, and nervous symptoms, so the animals in this group were sacrificed for ethical reasons. Necropsies revealed lesions specific to ASF infection. Groups immunized with preparations that did not contain CD154 and cdAMP together with the antigens in the immunogenic formulation showed the same clinical signs as control animals and were sacrificed between days 6 and 8 post-challenge. Animals immunized with the p72t-CD154 chimera combined or not with p30-CD154 + cdAMP were able to overcome the challenge without clinical manifestations of the disease (Figure 14B).No macroscopic pathological lesions compatible with PPA were observed at 28 dpc when all animals were sacrificed.
[0100] The presence of virus in blood and oral swabs after challenge was demonstrated in animals in the control group and in those that received antigens that did not simultaneously contain CD154 and cdAMP. Blood and oral swab samples from groups 2 and 6 were negative for ASF by both PCR and FACS at all times studied (Table 1).
[0101]
[0102] The data that does not appear in the table is because they presented a clear deterioration in health and were sacrificed for ethical reasons.
Claims
CLAIMS FORMULATION FOR ORAL IMMUNIZATION OF PIGS 1. An oral immunogenic formulation comprising: i) an immunologically relevant chimeric antigen of a pathogenic microorganism of pigs fused to the CD154 molecule of pigs, i) an adjuvant selected from the family of cyclic d-nucleotide monophosphates and iii) an excipient acceptable for oral immunization.
2. The formulation of claim 1 characterized in that the antigen comprises the chimeric protein containing the extracellular segment of the E2 protein of the Classical Swine Fever Virus (CSFV) and the molecular adjuvant CD154 of pigs consisting of SEQ ID NO:
1.
3. The formulation of claim 1 characterized in that the antigen comprises a combination of chimeric proteins consisting of the p72t and p30 proteins of the African Swine Fever Virus (ASFV), both fused to the molecular adjuvant CD154 of pigs consisting of the sequences SEQ ID NO: 2 and SEQ ID NO: 3, respectively.
4. The formulation of claim 1 wherein the adjuvant selected from the family of cyclic dinucleotide monophosphates is cyclic adenosine dimonophosphate (cdAMP).
5. The formulation of claim 4 which is formulated together with some cereal as bait.
6. The immunogenic formulation of claim 5 in which the bait is made from rice.
7. The formulation of claim 1 containing a concentration between 100 pg and 1 mg of the chimeric antigen diluted in 100 pg - 2000 pg of the adjuvant of the cyclic dinucleotide monophosphate family.
8. A method of inducing an immune response against the classical swine fever virus (CSFV) characterized in that a formulation comprising a chimeric antigen formed by i) the extracellular segment of the E2 protein of CSFV and the molecular adjuvant CD 154 of pigs is administered orally to a pig and consisting of SEQ ID NO:1 and i) an adjuvant selected from the family of cyclic d-nucleotide monophosphates.
9. The method of claim 8 wherein the formulation is administered as bait.
10. A method of inducing an immune response against the African swine fever virus (ASFV) characterized in that a formulation comprising: i) a combination of the chimeric proteins p72t and p30 of the ASFV, both fused to the molecular adjuvant CD154 of pigs consisting of the sequences SEQ ID NO: 2 and SEQ ID NO: 3, and i) an adjuvant selected from the family of cyclic dinucleotide monophosphates, is administered orally to a pig.
11. The method of claim 10, wherein the formulation is administered as bait.
Citation Information
Patent Citations
Chimeric vaccine antigens against classical swine fever virus
EP1994943A2
